Sugi Predict

Sugi Predict / Targets / KLK7

KLK7

Kallikrein-7 · P49862 · KLK7 on Sugi Atlas →

48,822 patent compounds predicted against KLK7, 25,470 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL361290 SCHEMBL361290 0.54 11/20
SCHEMBL361291 SCHEMBL361291 0.54 11/20
SCHEMBL317876 SCHEMBL317876 0.64 9/20
SCHEMBL360673 SCHEMBL360673 0.59 9/20
SCHEMBL360674 SCHEMBL360674 0.59 9/20
SCHEMBL360652 SCHEMBL360652 0.68 8/20
SCHEMBL360653 SCHEMBL360653 0.68 8/20
SCHEMBL359759 SCHEMBL359759 0.57 8/20
SCHEMBL359760 SCHEMBL359760 0.57 8/20
SCHEMBL247530 SCHEMBL247530 0.54 8/20
SCHEMBL360231 SCHEMBL360231 0.54 7/20
SCHEMBL360232 SCHEMBL360232 0.54 7/20
SCHEMBL279567 SCHEMBL279567 0.43 7/20
SCHEMBL360678 SCHEMBL360678 0.66 6/20
SCHEMBL360679 SCHEMBL360679 0.66 6/20
SCHEMBL759185 SCHEMBL759185 0.47 6/20
SCHEMBL582271 SCHEMBL582271 0.45 6/20
SCHEMBL433353 SCHEMBL433353 0.42 6/20
SCHEMBL85867 SCHEMBL85867 0.55 5/20
SCHEMBL54187 SCHEMBL54187 0.51 5/20

Clinical trials — most relevant to KLK7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism PHASE4COMPLETED
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II PHASE3COMPLETED
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema PHASE3COMPLETED
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer PHASE2COMPLETED
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA PHASE1/PHASE2RECRUITING
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer PHASE2COMPLETED
Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer PHASE2COMPLETED
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery PHASE1/PHASE2COMPLETED
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer PHASE2COMPLETED
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke PHASE2COMPLETED
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies PHASE1/PHASE2UNKNOWN
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. PHASE2WITHDRAWN
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen PHASE2COMPLETED
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy PHASE2RECRUITING
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide PHASE2UNKNOWN
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME PHASE1COMPLETED
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients. PHASE1COMPLETED
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors PHASE1COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy EARLY_PHASE1NOT_YET_RECRUITING
Urinary Kallikrein and Hypertension: A Prospective Study nanCOMPLETED
The Contact Activation System and Ulcerative Colitis nanCOMPLETED
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion nanRECRUITING
A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland nanUNKNOWN
Predicting Prostate Biopsy Results With Biomarkers and mpMRI. nanCOMPLETED
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer nanCOMPLETED
Can Nephrocheck™ Predict the Reversibility of Early, Acute Kidney Injury During Septic Shock? nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia nanCOMPLETED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KLK7 binder may also engage these)

ProteinNameSimilarity
P09582 — 0.987 P09582 →
KLK3 Prostate-specific antigen 0.987 landscape →
Q91VE3 — 0.987 Q91VE3 →
KLK2 Kallikrein-2 0.984 landscape →
Q07276 — 0.984 Q07276 →
Q28773 — 0.983 Q28773 →
P56435 — 0.983 P56435 →
P33619 — 0.983 P33619 →
P50341 — 0.983 P50341 →
P09650 — 0.982 P09650 →
Q03238 — 0.982 Q03238 →
KLK6 Kallikrein-6 0.982 landscape →
CMA1 Chymase 0.981 landscape →
Q00356 — 0.981 Q00356 →
KLK13 Kallikrein-13 0.981 landscape →
O46683 — 0.981 O46683 →
Q76B45 — 0.981 Q76B45 →
P21812 — 0.980 P21812 →
KLK5 Kallikrein-5 0.980 landscape →
Q6DT45 — 0.980 Q6DT45 →
P36369 — 0.980 P36369 →
P97592 — 0.980 P97592 →
KLK1 Kallikrein-1 0.980 landscape →
P50339 — 0.979 P50339 →
P50342 — 0.978 P50342 →
P21844 — 0.978 P21844 →
A7WPL7 — 0.978 A7WPL7 →
P36368 — 0.978 P36368 →
O35205 — 0.978 O35205 →
P80219 — 0.978 P80219 →